join us
Be a game changer with the Morphic Team
Our scientific founder, Tim Springer, once said that science is a team sport. Innovation happens through sharing diverse ideas and perspectives. All we need is dedication, faith, and love to develop innovative science and provide hope for patients.
What we value most
We take pride in our shared values that define who we are.
We respect patients, employees & their families. We do this for them.
We tackle challenging & meaningful problems with our absolute best effort every day.
We do what we say.
 We will not stop until we deliver meaningful medicines to patients.
We build strong, diverse, trusting teams to deliver meaningful medicines.
We find beauty in everything we do.
Voices from Morphic
We take pride in our shared values that define who we are.
Slide 1

“I love working at Morphic because of the fun, collaborative, and supportive culture. I feel that Morphic is really invested in my professional growth. I have learned so many new scientific skills while working here and I have had multiple opportunities to showcase my work. I also love the communication we have between different groups within the company. I feel that I can always walk by anyone’s desk or office and chat with them about what I’m working on or ask for advice.”

Liz Konopka
Sr. Research Associate

Slide 1

“Interning at Morphic has been an amazing experience. Even during my short time, I was able to take ownership of projects and make meaningful contributions to various programs. In addition, Morphic encourages community and mentorship; I was able to connect with people from many different backgrounds and points in their career, learning from their experiences. I gained countless skills from this opportunity, and I have grown both professionally and personally.”

Emi Yuki
Co-op/Summer Intern

Slide 1

“Morphic is a truly great place to work. The dynamic environment keeps me engaged and challenges me to learn and grow each day. With the immense support of the experienced leadership and diverse team here, I've gained a unique breadth of experience early in my career that has enabled me to make significant impacts on our programs. With the freedom to job craft, I've also been able to explore the various facets of my role and shape a position that aligns with my passions and values. We're a culture focused on inclusion, embracing our differences, and using our combined talents to better the lives of our patients. Come join the team!”

Andy McTeague
Scientist II, Chemistry

Slide 1

“Morphic’s DE&I affinity group fosters a culture of diversity and inclusion by offering activities to unite our employees together, including the monthly DE&I lunch and learn, celebrating diverse cultural traditions and much more.”

Willa Zhou
Principal Scientist

Slide 1

"Working at MT has been an awesome experience. Being in the screening group, I generate data that a lot of people rely on. Because of this, I have developed and fine tuned my lab skills to be able to consistently deliver good data to people across multiple projects in the company. Outside of the lab I have gotten involved in our volleyball team and our Ragnar relay team which has been a great way to contribute to the already amazing culture that we have here."

Kevin McManus
Research Associate

Benefits & Opportunities
At Morphic, we pride ourselves on our people-first culture and that means we take our benefits seriously. Being part of the BioHub community, we can also take advantage of their perks such as on-site gym, café and ample free parking with electric vehicle charging stations and much more!
Learn more about Morphic’s current opportunities to shape the future of integrin therapeutics
Scroll to Top

Contact Us

TL1A and IL-23

Morphic is leveraging its structural biology expertise and medicinal chemistry capabilities to develop small molecule therapeutic candidates against non-integrin targets including TL1-A and IL-23. Inhibition of these pathways have potential as treatments for IBD through monotherapy and possibly in combination with other IBD treatment mechanisms including α4β7 inhibition.


Morphic is developing small molecule inhibitors of the integrin α5β1 based on research demonstrating that fibronectin integrin inhibition suppresses pulmonary arterial smooth muscle cell proliferation. Potential indications include severe pulmonary hypertensive disease including pulmonary arterial hypertension.

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8 (MORF-088)

Morphic is developing small molecule inhibitors of the integrin αvβ8 for potential uses in myelofibrosis and a combination immuno-oncology approach for the treatment of solid tumors. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can drive increased platelet production and potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.